Double-hit and double-protein-expression lymphomas: Aggressive and refractory lymphomas

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages e555-e567

  Sarkozy, Clémentine ^a,b   Traverse Glehen, Alexandra ^a,b   Coiffier, Bertrand ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE; BCL2 PROTEIN, HUMAN; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BCL2 GENE; BCL6 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE HIT LYMPHOMA; DOUBLE PROTEIN EXPRESSION LYMPHOMA; DRUG TARGETING; GENE IDENTIFICATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA; MOLECULAR GENETICS; NONHUMAN; ONCOGENE MYC; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SURVIVAL TIME; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY;

DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GENES, MYC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84957805391     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00005-4     Document Type: Review

References (83)

1. Kramer MHH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998, 92:3152-3162.
2. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 2006, 19:25-33.
3. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007, 92:1335-1342.
4. Lin P, Medeiros LJ High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica 2007, 92:1297-1301.
5. Coiffier B, Thieblemont C, van den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
6. Li S, Seegmiller AC, Lin P, et al. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol 2015, 28:208-217.
7. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011, 117:2319-2331.
8. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012, 30:3460-3467.
9. Vennstrom B, Sheiness D, Zabielski J, Bishop JM Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 1982, 42:773-779.
10. Meyer N, Penn LZ Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976-990.
11. Dang CV MYC on the path to cancer. Cell 2012, 149:22-35.
12. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982, 79:7824-7827.
13. Greenough A, Dave SS New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing. Curr Opin Hematol 2014, 21:326-332.
14. Aukema SM, Kreuz M, Kohler CW, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 2014, 99:726-735. the Molecular Mechanisms in Malignant Lymphomas Network Project.
15. Valera A, López-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013, 98:1554-1562. the Grup per l'Estudi dels Limfomes de Catalunya i Balears (GELCAB).
16. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009, 114:2273-2279.
17. Pedersen MO, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol 2014, 92:42-48.
18. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010, 28:3360-3365.
19. Boxer LM, Dang CV Translocations involving c-myc and c-myc function. Oncogene 2001, 20:5595-5610.
20. Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 2010, 95:597-603.
21. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001, 412:341-346.
22. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014, 166:891-901.
23. Xu X, Zhang L, Wang Y, et al. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review. Int J Clin Exp Pathol 2013, 6:788-794.
24. Horn H, Ziepert M, Wartenberg M, et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia 2015, 29:1564-1570.
25. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon. 4th edn.
26. Kanagal-Shamanna R, Medeiros LJ, Lu G, et al. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology 2012, 61:945-954.
27. Pillai RK, Sathanoori M, van Oss SB, Swerdlow SH Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol 2013, 37:323-332.
28. Wang W, Hu S, Lu X, Young KH, Medeiros LJ Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: clinicopathologic features of 11 cases. Am J Surg Pathol 2015, 39:1132-1139.
29. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012, 30:3452-3459.
30. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013, 121:2253-2263. the German High-Grade Non-Hodgkin Lymphoma Study Group.
31. Lynnhtun K, Renthawa J, Varikatt W Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis. Pathology 2014, 46:211-215.
32. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996, 87:265-272.
33. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013, 121:4021-4031.
34. Cook JR, Goldman B, Tubbs RR, et al. Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. Am J Surg Pathol 2014, 38:494-501.
35. Niitsu N, Okamoto M, Miura I, Hirano M Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009, 23:777-783.
36. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 2014, 124:2354-2361.
37. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012, 25:145-156.
38. Gebauer N, Bernard V, Gebauer W, Thorns C, Feller AC, Merz H TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations. Leuk Lymphoma 2015, 56:179-185.
39. Gebauer N, Bernard V, Feller AC, Merz H ID3 mutations are recurrent events in double-hit B-cell lymphomas. Anticancer Res 2013, 33:4771-4778.
40. Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJ, Schuster SJ 'Double-hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Haematol 2014, 166:369-374.
41. Zhou K, Xu D, Cao Y, Wang J, Yang Y, Huang M C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies. PLoS One 2014, 9:e95020.
42. Vaidya R, Witzig TE Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol 2014, 25:2124-2133.
43. Tzankov A, Xu-Monette ZY, Gerhard M, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 2014, 27:958-971.
44. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009, 94:935-943.
45. Cohen JB, Geyer SM, Lozanski G, et al. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer 2014, 120:1677-1685.
46. Pedersen MØ, Gang AO, Poulsen TS, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma-a single centre's experience. Eur J Haematol 2012, 89:63-71.
47. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010, 34:327-340.
48. Sun H, Savage KJ, Karsan A, et al. Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 2015, 15:341-348.
49. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009, 114:3533-3537.
50. Bellas C, García D, Vicente Y, et al. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma. PLoS One 2014, 9:e98169.
51. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012, 7:e33813.
52. Obermann EC, Csato M, Dirnhofer S, Tzankov A BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. J Clin Pathol 2009, 62:903-907.
53. Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol 2009, 40:645-652.
54. Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 2013, 98:255-263.
55. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013, 381:1817-1826.
56. Friedberg JW, Unger JM, Burack WR, et al. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 2014, 166:382-389.
57. Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014, 165:382-391.
58. Molina TJ, Canioni D, Copie-Bergman C, et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol 2014, 32:3996-4003.
59. Cheah CY, Oki Y, Westin JR, Turturro F A clinician's guide to double hit lymphomas. Br J Haematol 2015, 168:784-795.
60. Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011, 378:1858-1867. the Groupe d'Etude des Lymphomes de l'Adulte.
61. Dunleavy K, Fanale M, LaCasce A, et al. Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. Blood 2014, 124:395.
62. StiffPJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013, 369:1681-1690.
63. Puvvada S, StiffP, Leblanc M, et al. MYC associated and double protein lymphoma: subset analysis of SWOG S9704. Blood 2014, 124:1710.
64. + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012, 119:4619-4624.
65. Mottok A, Gascoyne RD Bromodomain inhibition in diffuse large B-cell lymphoma-giving MYC a brake. Clin Cancer Res 2015, 21:4-6.
66. Emadali A, Rousseaux S, Bruder-Costa J, et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med 2013, 5:1180-1195.
67. Trabucco SE, Gerstein RM, Evens AM, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res 2015, 21:113-122.
68. Boi M, Gaudio E, Bonetti P, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res 2015, 21:1628-1638.
69. Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Mol Cancer Ther 2014, 13:2886-2897.
70. Chio II, Yordanov G, Tuveson D MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. J Natl Cancer Inst 2014, 106:dju365.
71. Stellas D, Szabolcs M, Koul S, et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst 2014, 106:dju320.
72. Zappasodi R, Ruggiero G, Guarnotta C, et al. HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood 2015, 125:1768-1771.
73. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010, 11:1149-1159.
74. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19:202-208.
75. Kelly GL, Grabow S, Glaser SP, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014, 28:58-70.
76. Spender LC, Inman GJ Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res 2014, 6:27-38.
77. Gregory GP, Hogg SJ, Kats LM, et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia 2014, 29:1437-1441.
78. Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010, 9:2344-2353.
79. Cinar M, Rosenfelt F, Rokhsar S, et al. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res 2015, 39:730-738.
80. Cerchietti LC, Ghetu AF, Zhu X, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010, 17:400-411.
81. Mahadevan D, Morales C, Cooke LS, et al. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. PLoS One 2014, 9:e95184.
82. Kirschner AN, Wang J, van der Meer R, et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst 2015, 107:dju407.
83. Leskov I, Pallasch CP, Drake A, et al. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene 2013, 32:1066-1072.